{
  "abstract": "BACKGROUND: We aimed to provide pharmacokinetic-pharmacodynamic (PK/PD) rationale for selecting the optimal induction and maintenance dosing regimens in ANCA-associated vasculitis (AAV) using a population modelling approach based on PK, ANCA, and gammaglobulins data from a real-world cohort. METHODS: weekly for 4 weeks and 1000 mg on day 0 and 14) and maintenance regimens (500 mg every 6 months [Q6M], 500 mg Q6M starting at month 4, 1000 mg Q4M, 500 mg Q4M) were performed in 1000 virtual patients. Dosing regimens were compared using a clinical utility score that equally weighted the percentage of patients in serological remission and at risk of hypogammaglobulinaemia (<6 g/L). FINDINGS: The PK/PD model satisfactorily described the relationship between rituximab, gammaglobulins and ANCA concentrations over time. Both induction regimens resulted in a similar number of patients achieving serological remission and hypogammaglobulinaemia at 6 months. In the maintenance phase, increasing the dose (to 1000 mg) or the frequency of administration (Q4M versus Q6M) was associated with a higher number of patients with serological remission at month 24, but also with a higher risk of hypogammaglobulinaemia. In the maintenance phase, 500 mg Q6M (start at month 4 or 6), had a significantly higher utility score than 1000 mg Q4M. INTERPRETATION: This PK/PD study can inform clinical decisions regarding the choice between different rituximab induction and maintenance regimens in patients with AAV in daily practice. FUNDING: This study received no funding.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "name": "Blaise Pasquiers"
    },
    {
      "name": "Benoit Blanchet"
    },
    {
      "name": "Xavier Puéchal"
    },
    {
      "name": "Xavier Declèves"
    },
    {
      "name": "Pascal Cohen"
    },
    {
      "name": "Claire Goulvestre"
    },
    {
      "name": "Marion Casadevall"
    },
    {
      "name": "Inès Benhabiles"
    },
    {
      "name": "Michel Vidal"
    },
    {
      "name": "David Ternant"
    },
    {
      "name": "Benjamin Terrier"
    },
    {
      "name": "Alicja Puszkiel"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/em6fk4ya9zv48.bib",
  "cited_by": 3,
  "doi": "10.1016/j.ebiom.2025.105989",
  "fulltext_url": null,
  "id": "em6fk4ya9zv48",
  "issns": [
    "2352-3964"
  ],
  "landing_url": "https://hal.science/hal-05864961v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.imm"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "openalex",
      "2745|Vasculitis and related conditions"
    ]
  ],
  "openalex": "W4415900086",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-15",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/em6fk4ya9zv48.ris",
  "sources": [
    {
      "first_seen": "2026-11-15T12:20:48Z",
      "native_id": "hal-05864961",
      "source": "hal",
      "url": "https://hal.science/hal-05864961v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.imm",
      "subfield": "immunology"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.mhep",
      "subfield": "general"
    }
  ],
  "title": "Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients",
  "title_text": "Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:20:43Z",
  "url": "https://research.draconitic.com/paper/em6fk4ya9zv48",
  "venue": "EBioMedicine",
  "versions": []
}